{"id":"W2981809579","doi":"10.1093/ofid/ofz359.043","title":"884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies","year":2019,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Dosing; Medicine; Rilpivirine; Tolerability; Clinical endpoint; Regimen; Adverse effect; Internal medicine; Clinical trial; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy; Virology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001418838,0.0002464945,0.0005177263,0.00008073743,0.0001515579,0.00006026548,0.0001610389,0.00003610937,0.00009819307],"category_scores_gemma":[0.0001241063,0.0001499354,0.00007331009,0.0003838527,0.00007749575,0.0002781657,0.0002008229,0.000113325,0.00006181653],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000109082,"about_ca_system_score_gemma":0.0001236121,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007404026,"about_ca_topic_score_gemma":0.0007048152,"domain_scores_codex":[0.9986274,0.00007777233,0.0003419546,0.0003599108,0.0002398481,0.0003530967],"domain_scores_gemma":[0.9991465,0.0001616221,0.0001458338,0.0003387877,0.0001187738,0.00008853381],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0009462695,0.001883182,0.9377921,0.0001149922,0.00035792,0.00007678002,0.00646273,0.0000187533,0.0002509405,0.0004192663,0.007109713,0.04456742],"study_design_scores_gemma":[0.103112,0.04288125,0.6220927,0.007471746,0.001138245,0.0004392503,0.08467033,0.0002061724,0.02668856,0.01032458,0.0977207,0.00325456],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9847458,0.001653285,0.00001491322,0.001414433,0.0001391219,0.00244818,0.000027392,0.00002790149,0.009528954],"genre_scores_gemma":[0.9955025,0.0007102661,0.0001135265,0.000817932,0.00001639805,0.0003393516,0.00002711236,0.00002060651,0.002452344],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3156994,"threshold_uncertainty_score":0.6114187,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02739097346984783,"score_gpt":0.3417454218479364,"score_spread":0.3143544483780886,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}